Oral News and Research

RSS

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula.

19 May 2014

Registration now open for interactive one day workshop for GPs

Registration is now open for an interactive one day workshop in Brisbane, designed by GPs for GPs, that will cover five hot topics — including statin prescribing and whether the hype is justified on newer oral anticoagulants.

19 May 2014

Bacteria that cause gum disease also promote heart disease, shows study

A University of Florida study shows that the same bacteria that cause gum disease also promotes heart disease - a discovery that could change the way heart disease is diagnosed and treated. Researchers report their findings today at the annual meeting of the American Society for Microbiology.

19 May 2014

Bacteria in saliva may be indicative of pancreatic cancer

Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases, according to research presented today at the annual meeting of the American Society for Microbiology.

19 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

New tech could take light-based cancer treatment deep inside the body

Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin cancer.

15 May 2014

Inspire Medical Systems completes $40 million Series E financing

Inspire Medical Systems, Inc. announced today that it has completed a Series E financing of $40 million. The financing round was strategically timed to coincide with the commercial launch of the Inspire Upper Airway Stimulation (UAS) therapy in the United States.

15 May 2014

Rep. Jan Schakowsky visits Wockhardt plant, commends production expansion in Illinois

Rep. Jan Schakowsky visited Wockhardt's Morton Grove facility with a goal in mind: strengthening efforts to revitalize American manufacturing.

15 May 2014

OxThera granted new patents for treatment of hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the last year.

15 May 2014

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders, convened more than 1700 researchers, delegates, autism specialists and students from 40 countries for the 13th Annual International Meeting for Autism Research (IMFAR), the world's largest scientific gathering on autism research, from May 15 through May 17 at the Atlanta Marriott Marquis in Atlanta, GA.

15 May 2014

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

15 May 2014

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain.

15 May 2014

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer.

15 May 2014

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

A comparatively new form of a medication for alcohol and opioid dependence that's injected once a month instead of taken orally once a day appears to be significantly more effective than some other medications - because more patients actually continue the prescribed regimen.

15 May 2014

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

Breastfeeding, tubal ligation - also known as having one's "tubes tied" - and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania's Basser Research Center for BRCA and the Abramson Cancer Center.

15 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Intensive insulin treatment improves survival for diabetic heart attack patients

Long-term follow-up of the DIGAMI 1 trial – a landmark study of type 2 diabetes in Sweden – shows that intensive insulin treatment prolonged life by more than 2 years in patients with diabetes after a heart attack, compared with standard treatment for diabetes, reports Dr Viveca Ritsinger from the Unit of Cardiology of the Department of Medicine, Karolinska Institute, Stockholm, Sweden and colleagues in The Lancet Diabetes & Endocrinology.

14 May 2014

Oral News and Research

USPTO grants two additional patents to SeroVital-hgh formula

Registration now open for interactive one day workshop for GPs

Bacteria that cause gum disease also promote heart disease, shows study

Bacteria in saliva may be indicative of pancreatic cancer

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

New tech could take light-based cancer treatment deep inside the body

Inspire Medical Systems completes $40 million Series E financing

Rep. Jan Schakowsky visits Wockhardt plant, commends production expansion in Illinois

OxThera granted new patents for treatment of hyperoxaluria

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Intensive insulin treatment improves survival for diabetic heart attack patients

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News